Option chain shows key data for Sandoz Group's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Sandoz Group.

Sandoz Group (OTC:SDZNY) Stock, Option Chain

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Amgen stock

Biotech

Large Cap

News

Health Care

Legal

General

AMGN

SDZNY

SDZXF

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the inflammatory disease market.

Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug

Cambridge,,Ma,,Usa,-,June,29,,2022:,Biogen,Logo,Is

Government

Topics

BIIB

Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing the impact.

NHS England&#39;s Transition From Biogen&#39;s Drug To Sandoz&#39;s Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects

biotech shutter

Movers

Trading Ideas

CHRS

Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&amp;D, and plans clinical trials in hepatocellular carcinoma and NSCLC.

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Sandoz Group AG

Press Releases

Francisco Ballester to retire; Peter Stenico appointed President Region International

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

Sandoz reports strong FY 2024 results and Q4 2024 sales

Sandoz signs landmark supply and manufacturing agreement

Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Sandoz Group

Screenshot 2024-10-01 at 5.30.51 PM

Cannabis

Psilocybin&#39;s Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines

Comments

Sandoz Group

Sandoz Group (SDZNY) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell